Compare BROS & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BROS | ALKS |
|---|---|---|
| Founded | 1992 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 8.7B |
| IPO Year | 2021 | 2012 |
| Metric | BROS | ALKS |
|---|---|---|
| Price | $51.10 | $49.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 20 | 14 |
| Target Price | ★ $76.40 | $43.43 |
| AVG Volume (30 Days) | ★ 4.2M | 1.6M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.24 | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $1,638,159,000.00 | $1,475,899,000.00 |
| Revenue This Year | $27.34 | $24.26 |
| Revenue Next Year | $23.01 | $4.47 |
| P/E Ratio | $126.76 | ★ N/A |
| Revenue Growth | ★ 27.88 | N/A |
| 52 Week Low | $44.58 | $25.17 |
| 52 Week High | $74.65 | $55.67 |
| Indicator | BROS | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 39.38 | 49.72 |
| Support Level | $49.89 | $47.66 |
| Resistance Level | $54.45 | $51.25 |
| Average True Range (ATR) | 1.96 | 1.49 |
| MACD | 0.05 | -0.08 |
| Stochastic Oscillator | 47.07 | 50.92 |
Dutch Bros Inc is an operator and franchisor of drive-thru coffee shops that are focused on serving hand-crafted beverages. The company's hand-crafted beverage-focused lineup features hot and cold espresso-based beverages, cold brew coffee products, proprietary energy drinks, tea, lemonade, smoothies, and other beverages. The company has two reportable operating segments Company-operated shops and Franchising. It derives maximum revenue from Company-operated shops.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.